A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans.
Yamakawa
Jun'ichi
J
Takahashi
Takashi
T
Itoh
Tohoru
T
Kusaka
Kazuya
K
Kawaura
Ken
K
Wang
Xin Qui
XQ
Kanda
Tsugiyasu
T
D052242:Adiponectin; D000368:Aged; D001162:Arteriosclerosis Obliterans / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013386:Succinates / Q000627:therapeutic use*
D052242:Adiponectin; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; D012702:Serotonin Antagonists; D013386:Succinates; C064294:sarpogrelate